Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdings, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Alethia Young has reiterated an Overweight rating on ALX Oncology Holdings (NASDAQ:ALXO) and maintained a price target of $18.
September 12, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on ALX Oncology Holdings and maintained a price target of $18.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for ALX Oncology Holdings. The maintained price target of $18 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100